<br>        Inclusion Criteria:<br><br>          -  Subject is willing to sign and date the study Patient Informed Consent Form.<br><br>          -  Subject is indicated for a CRT device according to local guidelines.<br><br>          -  Sinus Rhythm at time of enrollment<br><br>          -  Complete Left Bundle Branch Block (LBBB) as documented on an ECG (within 30 days prior<br>             to enrollment). Strauss Criteria used for LBBB.<br><br>          -  Intrinsic, normal AV conduction as documented on an ECG by a PR interval less than or<br>             equal to 200ms (within 30 days prior to enrollment).<br><br>          -  Left ventricular ejection fraction less than or equal to 35% (documented within 180<br>             days prior to enrollment).<br><br>          -  NYHA class II, III or IV (documented within 30 days prior to enrollment) despite<br>             optimal medical therapy. Optimal medical therapy is defined as maximal tolerated dose<br>             of Beta-blockers and a therapeutic dose of ACE-I, ARB or Aldosterone Antagonist.<br><br>        Exclusion Criteria:<br><br>          -  Subject is less than 18 years of age (or has not reached minimum age per local law).<br><br>          -  Subject is not expected to remain available for at least 2 years of follow-up visits.<br><br>          -  Subject has permanent atrial arrhythmias for which pharmacological therapy and/or<br>             cardioversion have been unsuccessful or have not been attempted<br><br>          -  Subject is, or previously has been, receiving cardiac resynchronization therapy.<br><br>          -  Subject is currently enrolled or planning to participate in a potentially confounding<br>             drug or device trial during the course of this study. Co-enrollment in concurrent<br>             trials is only allowed when documented pre-approval is obtained from the Medtronic<br>             study manager.<br><br>          -  Subject has unstable angina, or experienced an acute myocardial infarction (MI) or<br>             received coronary artery revascularization (CABG) or coronary angioplasty (PTCA)<br>             within 30 days prior to enrollment.<br><br>          -  Subject has a mechanical tricuspid heart valve or is scheduled to undergo valve repair<br>             or valve replacement during the course of the study.<br><br>          -  Subject is post heart transplant (subjects on the heart transplant list for the first<br>             time are not excluded).<br><br>          -  Subject has a limited life expectancy due to non-cardiac causes that would not allow<br>             completion of the study.<br><br>          -  Subject is pregnant (if required by local law, women of child-bearing potential must<br>             undergo a pregnancy test within seven days prior to device implant).<br><br>          -  Subject meets any exclusion criteria required by local law.<br>